The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VENCLEXTA Abbvie Pty Ltd
Product name
VENCLEXTA
Sponsor
Accepted date
May-2024
Active ingredients
venetoclax
Proposed indication
For the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Application type
C (new indication)
Publication date
May-2024